RU2018131359A - Модуляция гипоксии, ассоциированной с инсультом - Google Patents
Модуляция гипоксии, ассоциированной с инсультом Download PDFInfo
- Publication number
- RU2018131359A RU2018131359A RU2018131359A RU2018131359A RU2018131359A RU 2018131359 A RU2018131359 A RU 2018131359A RU 2018131359 A RU2018131359 A RU 2018131359A RU 2018131359 A RU2018131359 A RU 2018131359A RU 2018131359 A RU2018131359 A RU 2018131359A
- Authority
- RU
- Russia
- Prior art keywords
- nox
- peg
- protein
- covalently linked
- approximately
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 title claims 18
- 230000007954 hypoxia Effects 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 107
- 229920001223 polyethylene glycol Polymers 0.000 claims 107
- 102000004169 proteins and genes Human genes 0.000 claims 96
- 108090000623 proteins and genes Proteins 0.000 claims 96
- 238000000034 method Methods 0.000 claims 71
- 239000000203 mixture Substances 0.000 claims 41
- 208000006011 Stroke Diseases 0.000 claims 20
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 19
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 19
- 230000001146 hypoxic effect Effects 0.000 claims 17
- 238000010494 dissociation reaction Methods 0.000 claims 15
- 230000005593 dissociations Effects 0.000 claims 15
- 238000005829 trimerization reaction Methods 0.000 claims 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 239000001301 oxygen Substances 0.000 claims 13
- 241000253373 Caldanaerobacter subterraneus subsp. tengcongensis Species 0.000 claims 12
- 102000001554 Hemoglobins Human genes 0.000 claims 12
- 108010054147 Hemoglobins Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000000178 monomer Substances 0.000 claims 12
- 230000009257 reactivity Effects 0.000 claims 12
- 229920000642 polymer Polymers 0.000 claims 11
- 238000006467 substitution reaction Methods 0.000 claims 11
- 208000002381 Brain Hypoxia Diseases 0.000 claims 10
- 210000004556 brain Anatomy 0.000 claims 10
- 208000029028 brain injury Diseases 0.000 claims 10
- 241001599018 Melanogaster Species 0.000 claims 6
- 230000006378 damage Effects 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 238000006116 polymerization reaction Methods 0.000 claims 6
- 241000282414 Homo sapiens Species 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 101100121602 Caenorhabditis elegans gcy-35 gene Proteins 0.000 claims 3
- 241000282461 Canis lupus Species 0.000 claims 3
- 241000193401 Clostridium acetobutylicum Species 0.000 claims 3
- 102000008015 Hemeproteins Human genes 0.000 claims 3
- 108010089792 Hemeproteins Proteins 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 241000424623 Nostoc punctiforme Species 0.000 claims 3
- 241000700157 Rattus norvegicus Species 0.000 claims 3
- 241001223867 Shewanella oneidensis Species 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 241001515965 unidentified phage Species 0.000 claims 3
- 206010058558 Hypoperfusion Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 210000001130 astrocyte Anatomy 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000000274 microglia Anatomy 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000009524 hypoxic brain injury Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001067 neuroprotector Effects 0.000 claims 1
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/06—Processes for producing mutations, e.g. treatment with chemicals or with radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01247—Codeinone reductase (NADPH) (1.1.1.247)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01059—Protein geranylgeranyltransferase type I (2.5.1.59)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Environmental Sciences (AREA)
- Botany (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296009P | 2016-02-16 | 2016-02-16 | |
| US62/296,009 | 2016-02-16 | ||
| PCT/US2017/018233 WO2017143104A1 (en) | 2016-02-16 | 2017-02-16 | Modulation hypoxia associated with stroke |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018131359A true RU2018131359A (ru) | 2020-03-17 |
| RU2018131359A3 RU2018131359A3 (enExample) | 2020-08-12 |
Family
ID=58191670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018131359A RU2018131359A (ru) | 2016-02-16 | 2017-02-16 | Модуляция гипоксии, ассоциированной с инсультом |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20200276265A1 (enExample) |
| EP (1) | EP3416673B1 (enExample) |
| JP (1) | JP2019511567A (enExample) |
| KR (1) | KR20180123034A (enExample) |
| CN (1) | CN109069582A (enExample) |
| AU (1) | AU2017219869A1 (enExample) |
| BR (1) | BR112018016829A2 (enExample) |
| CA (1) | CA3014651A1 (enExample) |
| DK (1) | DK3416673T3 (enExample) |
| ES (1) | ES2939181T3 (enExample) |
| IL (1) | IL261178A (enExample) |
| MX (1) | MX2018009881A (enExample) |
| RU (1) | RU2018131359A (enExample) |
| SG (2) | SG10202007517TA (enExample) |
| WO (1) | WO2017143104A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3922643A1 (en) * | 2013-01-07 | 2021-12-15 | Omniox, Inc. | Polymeric forms of h-nox proteins |
| WO2020037052A1 (en) | 2018-08-15 | 2020-02-20 | Omniox, Inc. | H-nox proteins for treating cardiovascular and pulmonary conditions |
| AU2022328718A1 (en) * | 2021-08-18 | 2025-01-09 | Omniox Inc. | H-nox proteins for organ preservation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6054427A (en) | 1997-02-28 | 2000-04-25 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
| AU2002346686A1 (en) * | 2001-12-07 | 2003-06-23 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| EP2463295A1 (en) | 2006-05-22 | 2012-06-13 | The Regents of The University of California | Compositions and methods for the delivery of oxygen |
| EP3922643A1 (en) * | 2013-01-07 | 2021-12-15 | Omniox, Inc. | Polymeric forms of h-nox proteins |
-
2017
- 2017-02-16 EP EP17708103.1A patent/EP3416673B1/en active Active
- 2017-02-16 BR BR112018016829A patent/BR112018016829A2/pt not_active IP Right Cessation
- 2017-02-16 JP JP2018561933A patent/JP2019511567A/ja active Pending
- 2017-02-16 AU AU2017219869A patent/AU2017219869A1/en not_active Abandoned
- 2017-02-16 CN CN201780023823.8A patent/CN109069582A/zh active Pending
- 2017-02-16 KR KR1020187026176A patent/KR20180123034A/ko not_active Withdrawn
- 2017-02-16 MX MX2018009881A patent/MX2018009881A/es unknown
- 2017-02-16 US US15/998,557 patent/US20200276265A1/en not_active Abandoned
- 2017-02-16 SG SG10202007517TA patent/SG10202007517TA/en unknown
- 2017-02-16 RU RU2018131359A patent/RU2018131359A/ru not_active Application Discontinuation
- 2017-02-16 SG SG11201806920SA patent/SG11201806920SA/en unknown
- 2017-02-16 CA CA3014651A patent/CA3014651A1/en not_active Abandoned
- 2017-02-16 WO PCT/US2017/018233 patent/WO2017143104A1/en not_active Ceased
- 2017-02-16 ES ES17708103T patent/ES2939181T3/es active Active
- 2017-02-16 DK DK17708103.1T patent/DK3416673T3/da active
-
2018
- 2018-08-15 IL IL261178A patent/IL261178A/en unknown
-
2020
- 2020-12-23 US US17/133,180 patent/US20210121521A1/en not_active Abandoned
-
2023
- 2023-04-27 US US18/308,203 patent/US20240026399A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018131359A3 (enExample) | 2020-08-12 |
| AU2017219869A1 (en) | 2018-08-30 |
| JP2019511567A (ja) | 2019-04-25 |
| MX2018009881A (es) | 2019-01-31 |
| KR20180123034A (ko) | 2018-11-14 |
| BR112018016829A2 (pt) | 2018-12-26 |
| ES2939181T3 (es) | 2023-04-19 |
| CN109069582A (zh) | 2018-12-21 |
| EP3416673A1 (en) | 2018-12-26 |
| US20200276265A1 (en) | 2020-09-03 |
| US20210121521A1 (en) | 2021-04-29 |
| CA3014651A1 (en) | 2017-08-24 |
| WO2017143104A1 (en) | 2017-08-24 |
| US20240026399A1 (en) | 2024-01-25 |
| EP3416673B1 (en) | 2022-11-02 |
| IL261178A (en) | 2018-10-31 |
| DK3416673T3 (da) | 2023-01-23 |
| SG11201806920SA (en) | 2018-09-27 |
| SG10202007517TA (en) | 2020-09-29 |
| WO2017143104A8 (en) | 2018-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matz et al. | Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions | |
| Schlager et al. | Laser stimulation of acupuncture point P6 reduces postoperative vomiting in children undergoing strabismus surgery | |
| Best et al. | Buffered lidocaine and bupivacaine mixture-the ideal local anesthetic solution? | |
| KR20200143407A (ko) | Cgrp를 억제하는데 사용하기 위한 신경독소 | |
| CA2873553C (en) | Use of modified vasoactive intestinal peptides in the treatment of hypertension | |
| HUE030922T2 (en) | Therapeutic and prophylactic procedures, applications and preparations containing annexin A5 | |
| Velásquez et al. | Ketoprofen is more effective than diclofenac after oral surgery when used as a preemptive analgesic: a pilot study | |
| US20170190746A1 (en) | Recombinant polypeptide for promoting scarless wound healing and bioadhesive material including the same | |
| WO2021008100A1 (zh) | 眼镜蛇神经毒素多肽对鸦片类药品痛觉过敏和耐受的抑制及对其镇痛的协同增效作用 | |
| Rolek et al. | Advancements and applications of laser technology in modern dentistry | |
| NZ542092A (en) | Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime | |
| JP2019511567A5 (enExample) | ||
| Bueno et al. | Delayed repair of the facial nerve and its negative impacts on nerve and muscle regeneration | |
| WO2022066845A1 (en) | Novel genetic vector approaches for aesthetics, aesthetic plastic surgery, cosmetic dermatology, and other uses | |
| KR20210030948A (ko) | 저산소증-관련 조직 손상을 치료하기 위한 투약 요법 | |
| Urbanek | Overview on foam sclerotherapy in the treatment of varicose veins | |
| Choi et al. | Obturator nerve block with botulinum toxin type B for patient with adductor thigh muscle spasm-a case report | |
| HUP0302574A2 (hu) | Aktivált VII alvadási faktor alkalmazása trombolitikus terápia által kiváltott nagy vérzések kezelésére | |
| Pudasaini et al. | Study of Single Subcutaneous Injection for Digital Block Using Lignocaine with Adrenaline | |
| Stümpflen et al. | Effects of transvenous regional guanethidine block in the treatment of critical finger ischemia | |
| CN112190687B (zh) | 一种用于减少皮肤创伤瘢痕的药物及其应用 | |
| CN116239701B (zh) | 一种融合蛋白及其应用 | |
| RU2456988C1 (ru) | Способ лечения посттравматического артрита коленного сустава | |
| FFPMANZCA et al. | TRANSLATIONAL RESEARCH SECTIONpme_741 262.. 273 Original Research Article CNSB004 (Leconotide) Causes Antihyperalgesia Without Side Effects When Given Intravenously: A Comparison with Ziconotide in a Rat Model | |
| ELIWA et al. | Ketamine plus nitroglycerin versus ketamine as adjuncts to lidocaine for intravenous regional anesthesia in adult patients undergoing hand surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210111 |